2023. Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s179. DOI:https://doi.org/10.25251/skin.7.supp.179.